LIver FRAilty Management IN Cirrhosis (LIFRAMIN)

Last updated: April 9, 2025
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Overall Status: Active - Recruiting

Phase

N/A

Condition

Weight Loss

Hyponatremia

Diet And Nutrition

Treatment

Aminolife Plus by Piemme Pharmatech, Italy

Clinical Study ID

NCT06573229
6409 - LIFRAMIN
  • Ages > 18
  • All Genders

Study Summary

The goal of this clinical trial is to compare food for special medical purposes (Aminolife Plus, by Piemme Pharmatech) vs. placebo in improving muscle mass and function in a cohort of cirrhotic patients.

The main questions it aims to answer are:

  • whether functional ability improves in cirrhotic-sarcopenic patients two months after taking the supplement compared with those not taking the supplement.

  • whether weight, body mass index (BMI), lean mass, muscle mass, metabolically active mass, and phase angle as per bioimpedance analysis (BIA) in cirrhotic-sarcopenic patients increase two months after taking the supplement compared with those not taking the supplement.

  • to assess quality-of-life indices in the two groups.

  • to assess differences in groups in terms of plasma metabolite production in the two groups

This is a spontaneous, no PROFIT, pilot interventional study in the form of a randomized clinical trial (RCT), double-blind.

All patients will undergo simple sarcopenia risk identification questions (SARC-F test). All patients recognized to be at risk will be randomized to receive.

  1. nutritional counseling according to guidelines + Aminolife plus 20 g/day (4 scoops) vs.

  2. nutritional counseling according to guidelines + placebo 20 g/day (4 scoops) for a total of 60 days (2 months).

The manufacturing company will provide the product and placebo free of charge. Patients will undergo, at the first visit and at the follow-up visit anthropometric measurements and body composition assessment (by bioimpedance analysis).

In addition, 1 blood sample for metabolomic analysis will be taken at the same visits.

The study will last 12 months.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Patients affected by Liver cirrhosis

  • at any stage of Child (A-B-C) with or without hepatocarcinoma

  • SARC-F suggestive of risk of sarcopenia

  • Age > 18 years

  • Ability to perform Liver Frailty Index test

  • Informed consent to participate in the study.

Exclusion

Exclusion Criteria:

  • SARC-F not suggestive of sarcopenia

  • inability to perform Liver Frailty Index test

  • absence of informed consent

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: Aminolife Plus by Piemme Pharmatech, Italy
Phase:
Study Start date:
August 02, 2024
Estimated Completion Date:
June 30, 2025

Study Description

patients will be randomly allocated within the two groups:

  1. nutritional counselling according to guidelines + Aminolife plus 20 g/day (4 scoops) vs.

  2. nutritional counselling according to guidelines + placebo 20 g/day (4 scoops)

The patients will be randomly allocated into two groups: the control group who will not take the treatment and the experimental group who will take the supplement. In detail, patients in the experimental group, in association with nutritional counselling, will take Aminolife plus 20 g/day (4 scoops) for two months (T0-T2).

Patients in the control group, in combination with nutritional counselling, will take placebo 20 g/day (4 scoops) for two months (T0-T2).

The division into the 2 groups will follow a block randomisation algorithm according to the Random Sorting procedure. The allocation sequence will be generated by means of the PASS2022 software.17 The allocation operator will be 'blinded' to the allocation group, just as the operator applying the treatment will not be involved in the evaluation of patients and results.

Connect with a study center

  • Emanuele Rinninella

    Rome, 00168
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.